syn-iso-Butyraldehyd-isopropylhydrazon | 17610-67-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: syn-iso-Butyraldehyd-isopropylhydrazon
• 英文别名: N-[(E)-2-methylpropylideneamino]propan-2-amine
• CAS: 17610-67-2
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: ZCOSDMGEBMHBGJ-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异丙基肼 、 异丁醛 以 乙醚 为溶剂， 生成 syn-iso-Butyraldehyd-isopropylhydrazon
  参考文献：
  名称：

  Ioffe,B.V. et al., Journal of Organic Chemistry USSR (English Translation), 1968, vol. 4, p. 957 - 962

  摘要：

  DOI：

文献信息

• Binding protein drug conjugates comprising anthracycline derivatives
  申请人：NBE-Therapeutics AG

  公开号：US10188745B2

  公开（公告）日：2019-01-29

  The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682 having the formula (i) or formula (ii) which further comprises a linker structure X-L1-L2-L3-Y.

  本发明涉及一种蒽环类（PNU）衍生物共轭物，包括具有式（i）或式（ii）的蒽环类 PNU-159682 衍生物，该衍生物进一步包括连接体结构 X-L1-L2-L3-Y。
• Methods of use of anti-CD123 antibodies and antigen-binding fragments thereof
  申请人：IMMUNOGEN, INC.

  公开号：US10442865B2

  公开（公告）日：2019-10-15

  The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the a chain of the interleukine 3 receptor, or IL-3Rα). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.

  本发明一般涉及与 CD123 抗原（白细胞介素 3 受体或 IL-3Rα 的 a 链）结合的抗体、其抗原结合片段、多肽和免疫结合剂。本发明还涉及使用此类 CD123 结合分子诊断和治疗疾病（如 B 细胞恶性肿瘤）的方法。
• Anti-CD123 antibodies and conjugates and derivatives thereof
  申请人：IMMUNOGEN, INC.

  公开号：US10875925B2

  公开（公告）日：2020-12-29

  The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the α chain of the interleukine 3 receptor, or IL-3Rα). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.

  本发明一般涉及与 CD123 抗原（白细胞介素 3 受体或 IL-3Rα 的 α 链）结合的抗体、其抗原结合片段、多肽和免疫结合剂。本发明还涉及使用此类 CD123 结合分子诊断和治疗疾病（如 B 细胞恶性肿瘤）的方法。
• Conjugates comprising cell-binding agents and cytotoxic agents
  申请人：ImmunoGen, Inc.

  公开号：US10988531B2

  公开（公告）日：2021-04-27

  The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.

  本发明涉及新型细胞结合剂-细胞毒剂共轭物，其中细胞结合剂（CBA）通过CBA上的2-羟乙基胺氧化得到的醛基与细胞毒剂共价连接。本发明还提供了制备本发明共轭物的方法。本发明进一步提供了使用本发明共轭物抑制哺乳动物异常细胞生长或治疗增殖性疾病的组合物和方法。
• Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
  申请人：IMMUNOGEN, INC.

  公开号：US11135308B2

  公开（公告）日：2021-10-05

  The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

  本发明涉及一种新型细胞结合剂-美登素类药物结合物，该结合物具有自毁肽键，更具体地说，涉及具有式(I)的结合物。本发明还提供具有式(II)、(III)、(IV)或(V)的新型美登素类化合物。此外，本发明还提供含有本发明化合物或结合物的组合物和方法，这些组合物和方法可用于抑制哺乳动物中异常细胞的生长或治疗增殖性疾病。